WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009140269) RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/140269    International Application No.:    PCT/US2009/043613
Publication Date: 19.11.2009 International Filing Date: 12.05.2009
IPC:
A61K 38/17 (2006.01), A61P 11/02 (2006.01)
Applicants: CLARASSANCE, INC. [US/US]; 9700 Great Seneca Highway Rockville, MD 20850 (US) (For All Designated States Except US).
PILON, Aprile L. [US/US]; (US) (For US Only)
Inventors: PILON, Aprile L.; (US)
Agent: EVANS, Barry; Kramer Levin Naftalis & Frankel LLP 1177 Avenue of the Americas New York, NY 10036 (US)
Priority Data:
61/052,861 13.05.2008 US
Title (EN) RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS
(FR) PROTÉINE RECOMBINÉE HUMAINE CC10 ET COMPOSITIONS LA CONTENANT POUR LE TRAITEMENT DE LA RHINITE NASALE
Abstract: front page image
(EN)The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.
(FR)La présente invention concerne de façon générale l'utilisation de la protéine recombinée humaine CC10 (rhCC10), également connue sous le nom d'utéroglobine recombinée humaine, comme agent thérapeutique dans le traitement de la rhinite nasale, de la sinusite nasale, de la rhinosinusite chronique, et de la polypose nasale. Plus particulièrement, l'invention concerne des procédés, y compris, globalement, les gammes posologiques critiques de rhCC10 et la voie d'administration intranasale, qui peuvent être utilisés pour traiter de façon sûre et efficace les pathologies susmentionnées. L'invention concerne en outre une composition utile pour l'administration de rhCC10 à des humains.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)